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Background: Vascular access for TAVI is usually obtained through the femoral route. However, many eligible patients have advanced 
atherosclerotic disease of the aorta and iliaco-femoral arteries, with an increased risk of vascular complications and stroke. Anatomically the left 
subclavian artery may be an attractive alternative for vascular access. We studied the feasibility and safety of TAVI using the left subclavian artery as 
primary access site.
methods: Between December 2008 and July 2012, one hundred and twenty six consecutive patients underwent TAVI using the Medtronic 
CoreValve®. All procedures were performed by a dedicated cardio-thoracic surgeon and interventional cardiologist under general anaesthesia. Pre-
operative angiography was used to assess eligibility for left subclavian and femoral access.
results: The left subclavian artery was used as access site in 109 patients (87%). During the study the proportion of patients treated with this 
approach increased from 65% (17/26) to 92% (92/100). Of these patients, 21% had a patent LIMA graft, 5% had a left-sided pacemaker. The 
procedural success rate was 97%, the median procedure time 55 minutes. Thirty-day mortality was 6%, with low rates of myocardial infarction (2%) 
and stroke (2%). Dissection of the subclavian artery was treated with stenting in 6% of patients.The rate of major or life threatening bleeding was 
13%. One-year survival was 70%.
conclusions: The left subclavian artery is a feasible access site in the large majority of TAVI patients, even those with LIMA grafts or left-sided 
pacemakers. The procedural success rate is high, with a low risk of 30-day mortality, stroke and vascular complications. Our results show that the left 
subclavian approach can be developed as access site of choice for TAVI.
